MERS-CoV spike protein: a key target for antivirals.
Identifieur interne : 000D08 ( Main/Exploration ); précédent : 000D07; suivant : 000D09MERS-CoV spike protein: a key target for antivirals.
Auteurs : Lanying Du [États-Unis] ; Yang Yang [États-Unis] ; Yusen Zhou [République populaire de Chine] ; Lu Lu [République populaire de Chine] ; Fang Li [États-Unis] ; Shibo Jiang [États-Unis]Source :
- Expert opinion on therapeutic targets [ 1744-7631 ] ; 2017.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (pharmacologie), Anticorps neutralisants (pharmacologie), Antiviraux (pharmacologie), Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient (), Humains, Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Peptides (pharmacologie), Pénétration virale ().
- MESH :
- pharmacologie : Anticorps monoclonaux, Anticorps neutralisants, Antiviraux, Peptides.
- traitement médicamenteux : Infections à coronavirus.
- virologie : Infections à coronavirus.
- Animaux, Conception de médicament, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Pénétration virale.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (pharmacology), Antibodies, Neutralizing (pharmacology), Antiviral Agents (pharmacology), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Drug Design, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), Peptides (pharmacology), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antiviral Agents, Peptides.
- drug effects : Middle East Respiratory Syndrome Coronavirus, Virus Internalization.
- drug therapy : Coronavirus Infections.
- virology : Coronavirus Infections.
- Animals, Drug Design, Humans.
Abstract
The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.
DOI: 10.1080/14728222.2017.1271415
PubMed: 27936982
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E55
- to stream PubMed, to step Curation: 000E55
- to stream PubMed, to step Checkpoint: 000C35
- to stream Ncbi, to step Merge: 001879
- to stream Ncbi, to step Curation: 001879
- to stream Ncbi, to step Checkpoint: 001879
- to stream Main, to step Merge: 000D11
- to stream Main, to step Curation: 000D08
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MERS-CoV spike protein: a key target for antivirals.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="2"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name><affiliation wicri:level="2"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name><affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea><wicri:noRegion>Beijing </wicri:noRegion></affiliation></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name><affiliation wicri:level="1"><nlm:affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai </wicri:regionArea><wicri:noRegion>Shanghai </wicri:noRegion></affiliation></author><author><name sortKey="Li, Fang" sort="Li, Fang" uniqKey="Li F" first="Fang" last="Li">Fang Li</name><affiliation wicri:level="2"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27936982</idno><idno type="pmid">27936982</idno><idno type="doi">10.1080/14728222.2017.1271415</idno><idno type="wicri:Area/PubMed/Corpus">000E55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E55</idno><idno type="wicri:Area/PubMed/Curation">000E55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E55</idno><idno type="wicri:Area/PubMed/Checkpoint">000C35</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C35</idno><idno type="wicri:Area/Ncbi/Merge">001879</idno><idno type="wicri:Area/Ncbi/Curation">001879</idno><idno type="wicri:Area/Ncbi/Checkpoint">001879</idno><idno type="wicri:Area/Main/Merge">000D11</idno><idno type="wicri:Area/Main/Curation">000D08</idno><idno type="wicri:Area/Main/Exploration">000D08</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">MERS-CoV spike protein: a key target for antivirals.</title><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="2"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name><affiliation wicri:level="2"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name><affiliation wicri:level="1"><nlm:affiliation>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>c State Key Laboratory of Pathogen and Biosecurity , Beijing Institute of Microbiology and Epidemiology , Beijing </wicri:regionArea><wicri:noRegion>Beijing </wicri:noRegion></affiliation></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name><affiliation wicri:level="1"><nlm:affiliation>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai , China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>d Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology , Fudan University , Shanghai </wicri:regionArea><wicri:noRegion>Shanghai </wicri:noRegion></affiliation></author><author><name sortKey="Li, Fang" sort="Li, Fang" uniqKey="Li F" first="Fang" last="Li">Fang Li</name><affiliation wicri:level="2"><nlm:affiliation>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>b Department of Pharmacology , University of Minnesota Medical School , Minneapolis , MN </wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="2"><nlm:affiliation>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Laboratory of Viral Immunology , Lindsley F. Kimball Research Institute, New York Blood Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic targets</title><idno type="eISSN">1744-7631</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Neutralizing (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Drug Design</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Peptides (pharmacology)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Anticorps neutralisants (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Peptides (pharmacologie)</term><term>Pénétration virale ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antiviral Agents</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Antiviraux</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Pénétration virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Minnesota</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></region><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><name sortKey="Li, Fang" sort="Li, Fang" uniqKey="Li F" first="Fang" last="Li">Fang Li</name><name sortKey="Yang, Yang" sort="Yang, Yang" uniqKey="Yang Y" first="Yang" last="Yang">Yang Yang</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></noRegion><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27936982
|texte= MERS-CoV spike protein: a key target for antivirals.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27936982" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |